Upper Gastrointestinal Tract Safety of Daily Oral Risedronate in Patients Taking NSAIDs: A Randomized, Double-Blind, Placebo-Controlled Trial

The results of this study show that risedronate regimens at 5 mg/d or 15 mg/d as well as once weekly at 35 mg or 50 mg are not associated with an increased frequency of upper GI tract adverse events, even in patients who have an increased risk for such events.